Get More Information on Transplantation Market - Request Sample Report
The Transplantation Market was estimated at USD 16.62 billion in 2023 and is poised to reach 37.3 billion in 2032 anticipated to expand at a compound annual growth rate approx. CAGR of 9.4% for the forecast period of 2024-2032.
One of the main drivers of market expansion is the rising need for innovative tissue transplantation products and organ transplantation for the treatment of organ failure. Common causes of organ failure include severe trauma, blood loss, poisoning, drug addiction, leukaemia, sepsis, and other acute disorders. Globally, there is a strong need for tissue and organ transplantation, particularly for the kidney, heart, liver, and lungs. Organ failure can be brought on by a variety of factors, including poor eating habits, alcohol intake, inactivity, and drug usage. Thus, a boost in transplanting product demand is anticipated shortly. After a transplant operation, patients are given potent immunosuppressive medications, which makes them more susceptible to infectious infections since their immune is compromised. This can be attributable to the drop-in transplantation rates that has occurred in several nations as a result of the COVID-19 issue.
The acute decline in market income in 2020 has also been attributed to the paucity of resources during the pandemic, including primary protective equipment, intensive care units, and blood supplies. An increase in the prevalence of acute illnesses, which in turn leads to an increase in the number of organ failures, can be blamed for the global rise in the demand for organs for transplant. For instance, the most frequent causes of end-stage renal illness, for which kidney transplantation or dialysis are the only curative choices, are diabetes and high blood pressure. The U.S. Department of Health & Human Services reports that in 2019, there were around 122,913 people in the country who were in need of organ transplants. As a result, there is a huge need for cutting-edge transplantation goods to address organ failure. In order to address these problems, the Health Resources and Services Administration (HRSA) of the United States government adopted an effort for modernising the organ procurement and transplantation networks. This concept focuses on the publication of fresh information on organ donors and transplants.
DRIVERS
Rising incidence of chronic illnesses & technological progress
Ageing population expanding.
The need for organ transplantation is being driven by the increasing prevalence of chronic illnesses such end-stage renal disease, liver cirrhosis, and heart failure. The need for organ transplants has increased as a result of improvements in surgical methods, organ preservation techniques, and immunosuppressive medication. Organ transplantation is more frequently needed as a result of the ageing population's increased susceptibility to organ failure. The quantity of organs accessible for transplant has increased because to better public education and awareness efforts on organ donation and transplantation.
RESTRAIN
Organ scarcity.
Inadequate infrastructure, High price.
There is a severe scarcity of organs available for transplant since the demand for organs considerably outweighs the supply. Establishing a strong transplantation infrastructure, including transplant centres, skilled medical professionals, and organ storage facilities, may be difficult for developing nations. Surgery, post-operative care, immunosuppressive drugs, and long-term follow-up may all add up during transplant treatments. For many people, affordability can be a major barrier.
OPPORTUNITY
Regenerative medicine with stem cells & organ bioengineering in growing number of government projects
Research breakthroughs in regenerative medicine and stem cell therapy have the potential to provide substitute treatments that might lessen the need for organ transplantation. Researchers are investigating the potential for developing bioengineered organs utilizing tissue engineering and 3D printing methods, which might solve the problem of an organ scarcity.
Governments throughout the world are putting regulations into place to encourage organ donation, simplify transplant procedures, and improve infrastructure, opening up prospects for market expansion.
CHALLENGES
Organ refusal, Legal and ethical concerns.
Problems following a transplant.
The possibility of organ rejection remains a substantial problem in transplantation, necessitating continued study and development, despite improvements in immunosuppressive medications. Organ transplantation includes intricate ethical issues, such as consent, allocation of organs, and the illicit organ trafficking, all of which provide problems for the market.
It's important to carefully monitor and treat patients who are undergoing transplantation since they may have problems including infections, organ malfunction, and immunosuppressive drug side effects.
The number of organs available for transplant may decline as a result of the conflict and its aftermath. Population shifts, rising death rates, and difficulties with organ transportation and procurement can all contribute to a scarcity of organs, worsening an already-existing issue with transplantation. Resources for healthcare, including as medical staff, equipment, and supplies, have been strained by the war. This may cause transplant procedures to take longer than expected, make it harder to provide post-transplant care, and restrict availability to essential immunosuppressive drugs. International exchanges and partnerships in the field of transplantation may be hampered by the ongoing war and geopolitical concerns. Travel restrictions, interrupted supply chains, and safety worries can make it difficult to share information, skills, and resources that are essential for progress in transplantation.
IMPACT OF ONGOING RECESSION
Funding for research and development projects, especially those involving transplantation, is frequently cut during recessions. This may affect the development of novel transplantation procedures, technologies, and immunosuppressive medications as well as the advancement of research studies, clinical trials, and other initiatives. The quantity of organ donations may be impacted by economic downturns. When people and families are struggling financially, it may be harder for them to consent to organ donation, which would reduce the number of organs that are available for transplant. Healthcare systems may experience financial difficulty during recessions since they may have to set aside funds to assist both the overall economic recovery and acute medical needs. As a result, transplantation programmes may get less financing, and the financial burden on healthcare providers and patients may grow.
By Product
Tissue Products
Immunosuppressive Drugs
Preservation Solution
By Application
Organ Transplantation
Tissue Transplantation
By End-Use
Hospitals
Transplant Centers
Others
REGIONAL ANALYSES
North America
With a market share of 40% in 2023, North America led the transplantation market, and it is anticipated that it will continue to do so during the research period. The expansion of the market is being supported by highly developed healthcare facilities and the local presence of many major biotechnology and medical device businesses, including Stryker, Arthrex, Inc., Zimmer Biomet, Medtronic, and Novartis AG. In the past ten years, there has been a growing disparity between the availability and demand of organs, such as kidneys, livers, and hearts, for transplantation. However, governments and non-governmental organisations (NGOs) from different nations are taking steps to motivate individuals to donate organs and save lives. The contribution procedure is now clearer and simpler thanks to new regulations and standards. The Hospital Organ Donor Campaign was begun by the Human Resource & Services Administration in April 2020. As a result, there were more organ donations than the previous year.
Asia Pacific
Due to expanding stem cell research to create in-vitro tissue and organs as well as improving healthcare infrastructure in Asian nations like India, Thailand, the Philippines, and Indonesia, the Asia Pacific market is anticipated to grow at the greatest pace over the forecast period.
Get Customized Report as per Your Business Requirement - Request For Customized Report
North America
USA
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Rest of Europe
Asia-Pacific
Japan
South Korea
China
India
Australia
Rest of Asia-Pacific
The Middle East & Africa
Israel
UAE
South Africa
Rest of the Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin American
The major players are Abbvie, Inc, Arthrex, Inc, Zimmer Biomet, Medtronic, Novartis AG, Strykers, 21st Century Medicine, BiolifeSolutions, Inc, Teva Pharmaceuticals, Veloxis Pharmaceutical and others players
Immucor, Inc:
November 2022, Werfen and TPG reached a deal for Werfen to purchase Immucor, Inc., a multinational business with a broad portfolio of transfusion diagnostics products. By incorporating the specialised diagnostics solution of Immucor, Inc., this will assist the business in expanding its product line.
Bio-Rad Laboratories:
A collaboration between Bio-Rad Laboratories, Inc. and F. Hoffmann-La Roche Ltd. was established in March 2021 to provide the full range of InteliQ products and Unity QC data management systems. As a result, Bio-Rad Laboratories, Inc.'s product variation was used by F. Hoffmann-La Roche Ltd. to improve its position in the diagnostics market.
| Report Attributes | Details |
| Market Size in 2023 | USD 16.62 Bn |
| Market Size by 2032 | USD 37.3 Bn |
| CAGR | CAGR of 9.4 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Tissue Products, Immunosuppressive Drugs, Preservation Solution) • By Application (Organ Transplantation, Tissue Transplantation) • By End-Use (Hospitals, Transplant Centers, Others) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Abbvie, Inc, Arthrex, Inc, Zimmer Biomet, Medtronic, Novartis AG, Strykers, 21st Century Medicine, BiolifeSolutions, Inc, Teva Pharmaceuticals, Veloxis Pharmaceutical and others |
| Key Drivers | • Rising incidence of chronic illnesses & technological progress • Ageing population expanding. |
| Market Opportunities | • Regenerative medicine with stem cells & organ bioengineering in growing number of government projects |
Ans: The CAGR Growth rate of the Transplantation Market is approx. CAGR 9.4% for the forecast period of 2024-2031.
Ans: The projected market size of Transplantation Market at USD 16.62 billion in 2023 and is poised to reach at 34.11 billion in 2031.
Ans: The major key players are Abbvie, Inc, Arthrex, Inc, Zimmer Biomet, Medtronic, Novartis AG, Strykers, 21st Century Medicine, BiolifeSolutions, Inc, Teva Pharmaceuticals, Veloxis Pharmaceutical and others.
Ans: An increase in the prevalence of acute illnesses, the introduction of technologically sophisticated goods, and an increase in the number of tissue banks are major drivers fueling the growth of the transplantation industry.
Ans: With a share of 40% in 2023, North America dominated the transplantation market. This is due to the presence of numerous significant biotechnology and medical device businesses in the area as well as the well-developed healthcare infrastructure.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.22.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Transplantation Market, By Product
8.1Tissue Products
8.2Immunosuppressive Drugs
8.3Preservation Solution
9. Transplantation Market, By Application
9.1Organ Transplantation
9.2 Tissue Transplantation
10. Transplantation Market, By End-Use
10.1 Hospitals
10.2Transplant Centers
10.3Others
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Transplantation Market by Country
11.2.2North America Transplantation Market By Product
11.2.3 North America Transplantation Market ByApplication
11.2.4 North America Transplantation Market By End-User
11.2.5 USA
11.2.5.1 USA Transplantation Market By Product
11.2.5.2 USA Transplantation Market by Application
11.2.5.3 USA Transplantation Market by End-User
11.2.6 Canada
11.2.6.1 Canada Transplantation Market by Product
11.2.6.2 Canada Transplantation Market by Application
11.2.6.3 Canada Transplantation Market by End-User
11.2.7 Mexico
11.2.7.1 Mexico Transplantation Market by Product
11.2.7.2 Mexico Transplantation Market by Application
11.2.7.3 Mexico Transplantation Market by End-User
11.8 Europe
11.8.1 Europe Transplantation Market by Country
11.8.2 Europe Transplantation Market by Product
11.8.3 Europe Transplantation Market by Application
11.8.4 Europe Transplantation Market by End-User
11.8.6 Germany
11.8.6.1 Germany Transplantation Market by Product
11.8.6.2 Germany Transplantation Market by Application
11.8.6.3 Germany Transplantation Market by End-User
11.8.7 UK
11.8.7.1 UK Transplantation Market by Product
11.8.7.2 UK Transplantation Market by Application
11.8.7.3 UK Transplantation Market by End-User
11.8.8 France
11.8.8.1 France Transplantation Market by Product
11.8.8.2 France Transplantation Market by Application
11.8.8.3 France Transplantation Market by End-User
11.9.9 Italy
11.3.9.1 Italy Transplantation Market by Product
11.3.9.2 Italy Transplantation Market by Application
11.3.9.3 Italy Transplantation Market by End-User
11.3.10 Spain
11.3.10.1 Spain Transplantation Market by Product
11.3.10.2 Spain Transplantation Market by Application
11.3.10.3 Spain Transplantation Market by End-User
11.3.11 The Netherlands
11.3.11.1 Netherlands Transplantation Market by Product
11.3.11.2 Netherlands Transplantation Market by Application
11.3.11.3 Netherlands Transplantation Market by End-User
11.3.11 Rest of Europe
11.3.11.1 Rest of Europe Transplantation Market by Product
11.3.11.2 Rest of Europe Transplantation Market by Application
11.3.11.3 Rest of Europe Transplantation Market by End-User
11.4 Asia-Pacific
11.4.1 Asia Pacific Transplantation Market by Country
11.4.2 Asia Pacific Transplantation Market by Product
11.4.3 Asia Pacific Transplantation Market by Application
11.4.4Asia Pacific Transplantation Market by End-User
11.4.6 Japan
11.4.6.1 Japan Transplantation Market by Product
11.4.6.2 Japan Transplantation Market by Application
11.4.6.3 Japan Transplantation Market by End-User
11.4.7 South Korea
11.4.7.1 South Korea Transplantation Market by Product
11.4.7.2 South Korea Transplantation Market by Application
11.4.7.3 South Korea Transplantation Market by End-User
11.4.8 China
11.4.8.1 China Transplantation Market by Product
11.4.8.2 China Transplantation Market by Application
11.4.8.3 China Transplantation Market by End-User
11.4.9 India
11.4.9.1 India Transplantation Market by Product
11.4.9.2 India Transplantation Market by Application
11.4.9.3 India Transplantation Market by End-User
11.4.10 Australia
11.4.10.1 Australia Transplantation Market by Product
11.4.10.2 Australia Transplantation Market by Application
11.4.10.3 Australia Transplantation Market by End-User
11.4.11 Rest of Asia-Pacific
11.4.11.1 APAC Transplantation Market by Product
11.4.11.2 APAC Transplantation Market by Application
11.4.11.3 APAC Transplantation Market by End-User
11.5 The Middle East & Africa
11.5.1 The Middle East & Africa Transplantation Market by Country
11.5.2 The Middle East & Africa Transplantation Market by Product
11.5.3 The Middle East & Africa Transplantation Market by Application
11.5.4The Middle East & Africa Transplantation Market by End-User
11.5.6 Israel
11.5.6.1 Israel Transplantation Market by Product
11.5.6.2 Israel Transplantation Market by End-User
11.5.6.3 Israel Transplantation Market by Application
11.5.7 UAE11.5.7.1 UAE Transplantation Market by Product
11.5.7.2 UAE Transplantation Market by Application
11.5.7.3 UAE Transplantation Market by End-User
11.5.8 South Africa
11.5.8.1 South Africa Transplantation Market by Product
11.5.8.2 South Africa Transplantation Market by Application
11.5.8.3 South Africa Transplantation Market by End-User
11.5.9 Rest of Middle East & Africa
11.5.9.1 Rest of Middle East & Asia Transplantation Market by Product
11.5.9.2 Rest of Middle East & Asia Transplantation Market by Application
11.5.9.3 Rest of Middle East & Asia Transplantation Market by End-User
11.6 Latin America
11.6.1 Latin America Transplantation Market by Country
11.6.2 Latin America Transplantation Market by Product
11.6.3 Latin America Transplantation Market by Application
11.6.4 Latin America Transplantation Market by End-User
11.6.6 Brazil11.6.6.1 Brazil Transplantation Market by Product
11.6.6.2 Brazil Africa Transplantation Market by Application
11.6.6.3Brazil Transplantation Market by End-User
11.6.7 Argentina
11.6.7.1 Argentina Transplantation Market by Product
11.6.7.2 Argentina Transplantation Market by Application
11.6.7.3 Argentina Transplantation Market by End-User
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Transplantation Market by Product
11.6.8.2 Rest of Latin America Transplantation Market by Application
11.6.8.3 Rest of Latin America Transplantation Market by End-User
12. Company profile
12.1 Abbvie.
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Products/Services/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Arthrex, Inc
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Products/Services/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Zimmer Biomet
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Products/Services/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Medtronic.
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Products/Services/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 Novartis AG
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Products/Services/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Strykers.
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Products/Services/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 21st Century Medicine
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Products/Services/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 BiolifeSolutions, Inc.
12.8.2 Financials
12.8.3 Products/Services/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
12.9 Teva Pharmaceuticals.
12.9.1 Market Overview
12.9.2 Financials
12.9.3 Products/Services/Offerings
12.9.4 SWOT Analysis
12.9.5 The SNS View
12.10 Veloxis Pharmaceutical
12.10.1 Market Overview
12.10.2 Financials
12.10.3 Products/Services/Offerings
12.10.4 SWOT Analysis
12.10.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share Analysis
13.3 Recent Developments
14. Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The AI in Healthcare Market Size was valued at USD 22.5 Billion in 2023 and will reach USD 370.14 Billion by 2032 & grow at a CAGR of 36.5% by 2024-2032.
The Dose Calibrator Market Size was valued at USD 1.5 Billion in 2023 and is expected to reach USD 2.1 Billion by 2032 and grow at a CAGR of 3.9% over the forecast period 2024-2032.
The Smart Healthcare Market size was USD 166 Billion in 2023 and is expected to Reach USD 441.30 Billion by 2031 and grow at a CAGR of 13% over the forecast period of 2024-2031.
The Liver Cancer Therapeutics Market was valued at USD 3.62 billion in 2023 and is expected to reach USD 19.13 billion by 2032 at a compound annual growth rate of 20.3% during the forecast period from 2024 to 2032.
The Non-Invasive Prenatal Testing (NIPT) Market is expected to reach USD 17.75 Bn by 2031 and was valued at USD 6.4 Bn in 2023, and grow at a CAGR of 13.6% over the forecast period of 2024-2031.
The Atrial Fibrillation Devices Market size was valued at USD 4.34 Bn in 2023 and is expected to reach USD 16.78 Bn by 2031 and grow at a CAGR of 18.4% over the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
